This encouraged us to investigate Nestin expression; as being a marker of immature vessels; and a proangiogenic factor (FLT1) in RCC, and to evaluate Nestin+ MVD and their impact on RCC progression and patients’ survival. Here, FLT1 is linked to renal cell carcinoma.